Action Required for Importers Impacted by COVID-19
Client Alert | 1 min read | 03.24.20
USTR Seeks Comments on Removal of Tariffs on Certain Imports from China that Assist the U.S. Coronavirus Response
The Office of the U.S. Trade Representative (USTR) is seeking comments to remove Section 301 tariffs on certain imports from China that could help support the United States COVID-19 response. The USTR recently granted approximately 200 exclusions from the tariffs on China that covered personal protective equipment products, including medical masks, examination gloves, antiseptic wipes, and other medical-care related items, as a response to the COVID-19 outbreak.
The March 20, 2020, notice is seeking comments on whether a medical-care product is “needed to respond to the COVID-19 outbreak.” The Comment window will be open until at least June 25, 2020, and may be extended.
Each comment specifically must identify the particular product of concern and explain precisely how the product relates to the response to the COVID-19 outbreak. This notice does not replace the current ongoing exclusion process. Comments may be submitted until June 25, 2020 (or until a later date if needed). However, to facilitate timely consideration, interested parties should submit comments as soon as possible.
Contacts
Insights
Client Alert | 10 min read | 03.27.25
FinCEN Axes Corporate Transparency Act’s Reporting Obligations for U.S. Companies and U.S. Persons
Since December of last year, the status of the CTA has been in a state of perpetual flux, following a dizzying series of federal court rulings and FinCEN announcements. On February 28, 2025, we reported that FinCEN paused enforcement actions for entities required to report under the CTA’s Beneficial Ownership Information Reporting Rule (BOI Rule) until FinCEN issued an interim final rule providing new guidance regarding the BOI Rule’s requirements and associated deadlines. Then, on March 2, 2025, Treasury went a step further, indicating that it would altogether cease enforcement against U.S. citizens and domestic reporting companies for violations of the BOI Rule, explaining that it would instead issue proposed rulemaking to narrow the scope of the BOI Rule to “foreign reporting companies” only and set new reporting deadlines.
Client Alert | 3 min read | 03.27.25
Client Alert | 3 min read | 03.27.25
MoCRA Under the Trump Era: A Look at FDA's Monitoring and Enforcement Two Months In
Client Alert | 4 min read | 03.27.25
